如果您要报告不良事件或产品投诉,请拨打礼来客户服务中心热线400-828-2059(手机),800-828-2059(座机)
艾乐明®(巴瑞替尼片)
本页包括过去5年在同行评审期刊上发表的礼来发起的临床试验。 以下列表仅限于与已批准使用的产品相关的出版物, 可能是非适应症的。(请参见产品完整处方信息链接)
如果您对下面未列出的礼来研究有任何疑问,或希望获得本页期刊出版物的电子版, 请联系下面的礼来客户服务中心以获得进一步的帮助。
巴瑞替尼在日本 NNS、SAVI 和 AGS 患者中的疗效和安全性
Efficacy and safety of baricitinib in Japanese patients with NNS, SAVI, and AGS
发表日期:2023-04-22
文献链接
巴瑞替尼联合外用皮质类固醇治疗中重度特应性皮炎成人患者的长期疗效(长达 68 周):源自研究 BREEZE-AD7 的治疗反应者、部分反应者和无反应者分析
Long-Term Efficacy (up to 68 Weeks) of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Analysis of Treatment Responders, Partial Responders and Nonresponders Originating from Study BREEZE-AD7
发表日期:2023-05-01
文献链接在一项随机试验中,接受长达 104 周治疗的中度至重度特应性皮炎成人中,巴瑞替尼治疗的医生和患者报告结局持续改善
Maintained Improvement in Physician- and Patient-Reported Outcomes with Baricitinib in Adults with Moderate-to-Severe Atopic Dermatitis who were Treated for up to 104 Weeks in a Randomized Trial
发表日期:2023-04-05
文献链接疼痛和疾病活动对疲劳改善的相对影响:两项 巴瑞替尼 3 期临床试验的结果
Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results from Two Baricitinib Phase 3 Clinical Trials
发表日期:2023-04-01
文献链接巴瑞替尼联合外用皮质类固醇治疗对外用皮质类固醇反应不足的中重度特应性皮炎儿科患者的疗效和安全性:3 期、随机、双盲、安慰剂对照的结果
Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled
发表日期:2023-03-31
文献链接在长期扩展研究 BREEZE-AD3 的随机子研究中,巴瑞替尼成功治疗中重度特应性皮炎患者后,与连续给药相比的减量或停药的疗效
Efficacy of downtitration or treatment withdrawal compared to continuous dosing, after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomised substudy from the long-term extension study, BREEZE-AD3
发表日期:2022-11-17
文献链接巴瑞替尼 治疗斑秃的两项 3 期试验
Two Phase 3 Trials of Baricitinib for Alopecia Areata
发表日期:2022-05-05
文献链接在美国临床试验 (BREEZE-AD5) 中使用巴瑞替尼治疗的特应性皮炎患者的日常日记中报告的症状缓解起效时间
Onset of Symptom Relief Reported in Daily Diaries in Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
发表日期:2022-01-28
文献链接在巴瑞替尼 3 期试验中,瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的贡献。
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
发表日期:2022-01-18
文献链接使用阿片类药物的类风湿关节炎患者的疼痛减轻:巴瑞替尼 3 期试验的事后分析
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
发表日期:2021-12-16
文献链接